Clinical Significance of Background Parenchymal Enhancement in Breast Cancer Risk Stratification

By sjmartinez • September 20, 2023

Murakami W, Mortazavi S, Yu T, Kathuria-Prakash N, Yan R, Fischer C, McCann KE, Lee-Felker S, Sung. Clinical Significance of Background Parenchymal Enhancement in Breast Cancer Risk Stratification. J Magn Reson Imaging. 2023 Sep 19. doi: 10.1002/jmri.29015. Epub ahead of print. PMID: 37724902.

Tags: background parenchymal enhancement (BPE), BRCA, breast MRI, Fellow, Hematology/Oncology, high-risk screening, lifetime risk, Publications

Hormone therapy use and duration with postoperative radiotherapy for recurrent prostate cancer: an individual patient data meta-analysis

Kishan AU, Sun Y, Parker CC, Sargos P, Sydes MR, Chabaud S, Brihoum M, Kalbasi TR, Steinberg ML, Valle LF, Taparra K, Shoag JE, Garcia[...]

A first-in-human phase 1 study of the SHP2 inhibitor BBP-398 in patients with advanced solid tumors

Falchook G, Braganca Xavier C, Van Veenhuyzen D, Malhotra J, Sadeghi S, Kalebasty AR, Wood L, Rahman F, Li E, Pak Y, Khalil M, Spira[...]

Socioeconomic disparities in long-term heart failure risk of trastuzumab with or without anthracyclines in early-stage breast cancer: a SEER-Medicare database analysis

Britten K, Lipsyc-Sharf M, Yang EH, McCloskey S, Sedrak MS, Teshome M, LaBarbera J, Bardia A, McAndrew N. Socioeconomic disparities in long-term heart failure risk[...]